CDIO.US Cardio Diagnostics Holdings Inc

Healthcare Biotechnology USA Stocks
1.89 USD
Close of Nov 13, 2026
0.9700 7.91
Market cap
USD 5.59M
P/E
-
P/B
0.98x
ROE
-117.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CDIO.US undervalued?

Graham number

The Graham number of Cardio Diagnostics Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cardio Diagnostics Holdings Inc fundamental analysis

No fundamental analysis for Cardio Diagnostics Holdings Inc yet.

Cardio Diagnostics Holdings Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic…

Full company profile